Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non–small-cell lung cancer and a performance status of 2

R Lilenbaum, R Axelrod, S Thomas… - Journal of Clinical …, 2008 - ascopubs.org
… On the basis of these observations, we conducted a randomized phase II trial to evaluate
these two strategies in the first-line management of advanced NSCLC patients with PS 2. We …

Randomized phase II study of gefitinib compared with placebo in chemotherapy-naive patients with advanced non–small-cell lung cancer and poor performance …

G Goss, D Ferry, R Wierzbicki, SA Laurie… - Journal of Clinical …, 2009 - ascopubs.org
… cancer (NSCLC) have a poor performance status (PS). PS is … based on the results of
randomized controlled studies. However, … This proof of principle randomized phase II study …

Randomized phase III trial of single-agent pemetrexed versus carboplatin and pemetrexed in patients with advanced non–small-cell lung cancer and Eastern …

M Zukin, CH Barrios, J Rodrigues Pereira… - Journal of clinical …, 2013 - ascopubs.org
… We conducted a prospective randomized phase III trial to compare single-agent pemetrexed
versus the combination of carboplatin and pemetrexed in the first-line management of …

[HTML][HTML] A randomized phase II trial of two schedules of docetaxel in elderly or poor performance status patients with advanced non-small cell lung cancer

R Lilenbaum, M Rubin, J Samuel, L Boros… - Journal of Thoracic …, 2007 - Elsevier
… We conducted a multicenter randomized phase II trial to evaluate two schedules of single-agent
docetaxel in the first-line treatment of elderly and performance status (PS) 2 patients with …

Randomized phase II trial of paclitaxel plus carboplatin or gemcitabine plus cisplatin in Eastern Cooperative Oncology Group Performance Status 2 non–small-cell …

C Langer, S Li, J Schiller, W Tester… - Journal of clinical …, 2007 - ascopubs.org
Purpose Appropriate therapy for Eastern Cooperative Oncology Group (ECOG) performance
status (PS) -2 patients with advanced non–small-cell lung cancer (NSCLC) remains …

Randomized phase III trial of gemcitabine and cisplatin vs. gemcitabine alone in patients with advanced non-small cell lung cancer and a performance status of 2: the …

A Morabito, V Gebbia, M Di Maio, S Cinieri, MG Viganò… - Lung cancer, 2013 - Elsevier
… On these bases, in 2008, we started a randomized phase 3 trial (CAPPA-2, Cisplatin Added
to Gemcitabine in Poor Performance Advanced NSCLC patients – PS2) to assess whether …

Randomized phase II study of two gemcitabine schedules for patients with impaired performance status (Karnofsky performance status≤ 70) and advanced non–small …

S Baka, L Ashcroft, H Anderson, M Lind… - Journal of clinical …, 2005 - ascopubs.org
… The primary objective of the study was to assess the change in Karnofsky performance status
Performance status was documented, and the SS14 questionnaires were administered …

… versus docetaxel/gemcitabine in the treatment of elderly or poor performance status patients with advanced nonsmall cell lung cancer: a randomized phase 3 trial of …

JD Hainsworth, DR Spigel, C Farley, DL Shipley… - Cancer, 2007 - Wiley Online Library
… .2, 5, 6 However, in a large phase 3 trial designed specifically for elderly patients, single-…
elderly and poor performance status patients, we performed a randomized phase 3 study that …

[HTML][HTML] … phase II trial of single-agent gemcitabine, vinorelbine, or docetaxel in patients with advanced non-small cell lung cancer who have poor performance status …

SS Leong, CK Toh, WT Lim, X Lin, SB Tan… - Journal of Thoracic …, 2007 - Elsevier
… was most marked in patients with performance status 3. … chemotherapy to patients with good
performance status (PS), … An important randomized study in elderly NSCLC patients done …

Randomized phase III study of chemoradiation with or without amifostine for patients with favorable performance status inoperable stage II-III non-small cell lung …

R Komaki, JS Lee, B Kaplan, P Allen, JF Kelly… - Seminars in radiation …, 2002 - Elsevier
A prospective randomized study was conducted to determine whether amifostine (Ethyol)
reduces the rate of severe esophagitis and hematologic and pulmonary toxicity associated with …